News

The V Foundation for Cancer Research Announces 2011 Translational Grant Recipients

For Immediate Release

Media Contact: Torrey Winchester

[email protected]

918-638-1413

 

The V Foundation for Cancer Research Announces 2011 Translational Grant Recipients

Grants Totaling $5.4 Million Awarded to Nine Researchers Focused in Bridging Gap Between Lab and Patients

 

(Cary, NC) – The V Foundation for Cancer Research, one of the nation’s leading cancer research fundraising organizations, has announced the nine recipients of their 2011 Translational Grants.  These nine grants have been awarded to elite researchers across the United States.

Translational Grants are $600,000, three-year commitments designed to bring lab discoveries to the field.  Often, information collected at the patient bedside can provide insight into laboratory findings and accelerate practical medical discoveries. This year’s nine recipients have concentrations in a variety of fields including leukemia, melanoma, and head and neck cancers.

“Each of the nine Translational grant recipients has already done tremendous work in the fight against cancer,” said Nick Valvano, CEO of The V Foundation for Cancer Research.  “The V Foundation is excited to provide grants to these outstanding researchers as they continue to make strides towards a cure.”

The V Foundation’s Scientific Advisory Board, comprised of some of the nation’s leading physicians and research scientists from prominent universities and cancer centers, supervises this competitive grant application process.  In The V Foundation’s 18-year history, over $100 million has been raised funding over 400 cancer grants nationwide to more than 100 institutions.  100 percent of all direct donations and proceeds of events through The V Foundation are donated directly to cancer research and related programs nationwide.

For more information on The V Foundation, please log onto www.jimmyv.org or call 1-800-4JimmyV.

About The V Foundation

The V Foundation for Cancer Research was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State basketball coach and ESPN commentator. Since 1993, The Foundation has raised more than $100 million to fund cancer research grants nationwide. It awards 100 percent of all direct cash donations and net proceeds of events directly to cancer research and related programs. Administrative and fundraising expenses are paid by the Foundation’s endowment. The Foundation awards grants through a competitive awards process strictly supervised by a Scientific Advisory Board. For more information on The V Foundation or to make a donation, please visit www.jimmyv.org.

 

Editors Note:      A complete list of the 2011 V Foundation Translational grant recipients follows:

 

V Foundation 2011 Translational Grant Recipients

Suzanne J. Baker, Ph.D.

Cynthia Wetmore, M.D., Ph.D.

St. Jude Children’s Research Hospital

Memphis, TN

Targeting PDGFR in Pediatric High-Grade Gliomas

Andrei Thomas-Tikhonenko, Ph.D.

Stephen Grupp, M.D., Ph.D.

Children’s Hospital of Philadelphia

Philadelphia, PA

Novel therapeutic targets in acute B-lymphoblastic leukemia

 

Richard Roden, Ph.D.

Sara Pai, M.D., Ph.D.

TC Wu, M.D., Ph.D.

John Hopkins University School of Medicine

Baltimore, MD

Treatment of Head and Neck cancer with an HPV vaccine

 

Iannis Aifantis, Ph.D.

Elizabeth A. Raetz, M.D.

New York University School of Medicine

New York, NY

Clinical Implications of TET Regulated DNA Methylation in Acute Lymphoblastic Leukemia

 

Leonard I. Zon, Ph.D.

Richard M. White, M.D.

Children’s Hospital Boston

Boston, MA

Cell Fate as a Target in Melanoma

Janice E. Mehnert, M.D.

Eileen P. White, Ph.D.

Cancer Institute of New Jersey

New Brunswick, NJ

Examining the Role of Autophagy in Melanoma Tumorigenesis

Faith M. Uckun, M.D., Ph.D.

Paul S. Gaynon, M.D.

Amanda M. Termuhlen, M.D.

Children’s Center for Cancer and Blood Diseases

Children’s Hospital Los Angeles

Los Angeles, CA

Funded by The V Foundation Wine Celebration

Directing Leukemia Cells to Self-Destruct Using Recombinant Human CD19-Ligand’s Trial Fusion Protein 

 

Carlos A. Ramos, M.D.

Ann M. Leen, Ph.D.

Dan L. Duncan Cancer Center at Baylor College of Medicine

Houston, TX

Most Closely HLA-Matched Allogeneic LMP1/2 – Specificed Cytotoxic T Lymphocytes for Treatment Patients with Relapsed Epstein-Barr Virus-Associated Lymphomas

 

Hua Eleanor Yu, Ph.D.

Stephen J. Forman, M.D.

Marcin Kortylewski, Ph.D.

Beckman Research Institute of the City of Hope

Duarte, CA

 Funded in Honor of Neil Aldoroty

Targeting STAT3 in Tumor and the Tumor Microenvironment by a Novel siRNA Technology to Treat Lymphoma

 

###